INNOVA CAPTAB LIMITED
Plot No. 320, Industrial Area, Phase-1,
Panchkula, Pin-134113, Haryana, India.
Phone: +91-172-4194500

07th November, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, "G" Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ('SEBI LODR Regulations'), we are enclosing herewith the Press Release issued by the Company on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2025.

The Press Release is available on the website of the Company at www.innovacaptab.com/corporate-governance

This is for your information and record.

Thanking you,

Yours faithfully,
For **Innova Captab Limited**

NEEHARIKA SHUKLA
Digitally signed by NEEHARIKA SHUKLA
Date: 2025.11.07 18:59:09 +05'30'

Neeharika Shukla
Company Secretary and Compliance Officer

Encl.: As above

INNOVA CAPTAB LIMITED

Press Release

Performance Review of Q2 and H1 FY26

Innova Captab Limited reported strong results for Q2 FY26, with Revenue from Operations at ₹ 380 crores and EBIDTA at ₹ 56 crores

Registered YoY Revenue growth of 19.5% and EBIDTA growth of 8%

Mumbai 7th November 2025: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its financial results for the quarter and half year ending September 30th, 2025.

Key Highlights

Q2 FY26 vs Q2 FY25

- Revenue from Operations registered stellar growth of 19.5% to ₹ 380.4 crores vs ₹ 318.2 crores
- Achieved EBITDA of ₹ 56.1 crores vs ₹ 51.9 crores in Q2 FY25. EBITDA margin for the quarter was 14.7%
- PAT for the quarter stood at ₹ 29.7 crores. PAT margin was 7.8%

H1 FY26 vs H1 FY25

- Revenues for H1 FY26 totalled to ₹ 731.9 crores vs ₹ 612.5 crores in H1 FY25
- Registered EBITDA of ₹ 112.6 crores vs ₹ 96.2 crores in H1 FY25. EBITDA margin was 15.4%
- Profit after tax was ₹ 60.7 crores. PAT margin was 8.3%

Commenting on the results, **Mr. Vinay Lohariwala, Managing Director – Innova Captab Limited** said **"Our strategic initiatives continue to deliver measurable outcomes, as evidenced by YoY revenue growth of 19.5% both in Q2 and H1 FY26 reaching ₹ 380 crores and ₹ 732 crores respectively.**

We witnessed healthy volume growth, underscoring the sustained demand momentum and operational efficiency achieved through our scale-up efforts.

During the quarter, our manufacturing capabilities were further strengthened with the successful inspection of our Cephalosporin plant in Baddi by the United Kingdom's Medicines and Healthcare products Regulatory Agency (UK-MHRA) and of our Jammu facility by the State Service of Ukraine on Medicines and Drugs Control (SMDC). These milestones underscore our adherence to global quality standards and reinforce our presence in key international markets.

With multiple growth levers in motion — including substantial room for scale-up, geographic diversification, and a robust product pipeline — we are well-positioned to sustain our growth trajectory and deliver a resilient performance across both our business verticals."

Financial Performance

***(amount in* ₹ crore except otherwise mentioned)**

Q2 FY26 vs Q2 FY25

Particulars	**Q2 FY26**	**Q2 FY25**	**YoY Growth**
Revenue from Operations	**380.4**	**318.2**	**19.5%**
EBITDA	**56.1**	**51.9**	**8%**
EBITDA Margin (%)	**14.7%**	**16.3%**	**(160 bps)**
Profit after Tax	**29.7**	**35.0**	**(15%)**

H1 FY26 vs H1 FY25

Particulars	**H1 FY26**	**H1 FY25**	**YoY Growth**
Revenue from Operations	**731.9**	**612.5**	**19.5%**
EBITDA	**112.6**	**96.2**	**17%**
EBITDA Margin (%)	**15.4%**	**15.7%**	**(30 bps)**
Profit after Tax	**60.7**	**64.5**	**(6%)**

About Innova Captab Limited

Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company in India with a comprehensive business model and presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides an elaborate suit of pharmaceutical products to over 300 clients in India and key international markets. Apart from this, the company has strong direct presence across India and international markets with its Branded Generics Business. The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA among others.

For more details, please visit www.innovacaptab.com

For more information, please contact:
Mr. Lokesh Bhasin/ Mr. Ayush Kumar Garg
Email: investors@innovacaptab.com / ayush.garg@innovacaptab.com

DISCLAIMER:
Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.